Research ExplorerPublicationsImpact of antibiotic intake on the incidence of extended-spe...

Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa

Standard

Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa. / Heinemann, Melina; Kleinjohann, Lukas; Rolling, Thierry; Winter, Doris; Hackbarth, Nina; Ramharter, Michael; Addo, Marylyn; Eibach, Daniel; Phillips, Richard O; Owusu-Ofori, Alex; Vinnemeier, Christof D.

In: CLIN MICROBIOL INFEC, Vol. 29, No. 3, 03.2023, p. 340-345.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heinemann, M, Kleinjohann, L, Rolling, T, Winter, D, Hackbarth, N, Ramharter, M, Addo, M, Eibach, D, Phillips, RO, Owusu-Ofori, A & Vinnemeier, CD 2023, 'Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa', CLIN MICROBIOL INFEC, vol. 29, no. 3, pp. 340-345. https://doi.org/10.1016/j.cmi.2022.09.008

APA

Heinemann, M., Kleinjohann, L., Rolling, T., Winter, D., Hackbarth, N., Ramharter, M., Addo, M., Eibach, D., Phillips, R. O., Owusu-Ofori, A., & Vinnemeier, C. D. (2023). Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa. CLIN MICROBIOL INFEC, 29(3), 340-345. https://doi.org/10.1016/j.cmi.2022.09.008

Vancouver

Heinemann M, Kleinjohann L, Rolling T, Winter D, Hackbarth N, Ramharter M et al. Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa. CLIN MICROBIOL INFEC. 2023 Mar;29(3):340-345. https://doi.org/10.1016/j.cmi.2022.09.008

Bibtex

@article{23ab69471a794715a5956f2d7a6fc539,
title = "Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa",
abstract = "OBJECTIVES: The global prevalence of intestinal extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) is approximately 17% in communities, with significant variations among regions. This longitudinal study aimed to assess the impact of antibiotic intake on the incidence of intestinal ESBL-PE in Ghanaian pharmacy customers outside of hospitals.METHODS: Screening for ESBL-PE was performed in four independent pharmacies in Kumasi, Ghana, using rectal swabs and an ESBL-PE-selective medium. Pharmacy customers purchasing antibiotics were recruited, and those buying non-antibiotic drugs served as controls. Participants who were negative for ESBL-PE provided follow-up swabs for up to 28 days.RESULTS: At baseline, 302 (75%) of 404 participants were colonized with ESBL-PE. Sixty-three participants who were negative for ESBL-PE at baseline received per-protocol follow-up, including 28 individuals who took antibiotics and 35 controls. The cumulative proportions of ESBL-PE in the antibiotics and control groups were 71% (20/28) and 54% (19/35) at the first follow-up (p 0.258), 86% (24/28) and 80% (28/35) at the second follow-up (p 0.741) and 86% (24/28) and 94% (33/35) at the third follow-up (p 0.393), respectively.DISCUSSION: The rate of intestinal ESBL-PE carriage among pharmacy customers outside of hospitals was higher than expected at baseline and further increased during the 28 days of follow-up, irrespective of antibiotic intake. This alarming finding needs to be considered in the antibiotic treatment of outpatients and emphasizes the urgent need for improved prevention strategies, development of new antibiotic drugs and potential future elimination strategies. Further longitudinal studies on ESBL-PE in African communities, also outside of pharmacy settings, are required.",
author = "Melina Heinemann and Lukas Kleinjohann and Thierry Rolling and Doris Winter and Nina Hackbarth and Michael Ramharter and Marylyn Addo and Daniel Eibach and Phillips, {Richard O} and Alex Owusu-Ofori and Vinnemeier, {Christof D}",
note = "Copyright {\textcopyright} 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.",
year = "2023",
month = mar,
doi = "10.1016/j.cmi.2022.09.008",
language = "English",
volume = "29",
pages = "340--345",
journal = "CLIN MICROBIOL INFEC",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa

AU - Heinemann, Melina

AU - Kleinjohann, Lukas

AU - Rolling, Thierry

AU - Winter, Doris

AU - Hackbarth, Nina

AU - Ramharter, Michael

AU - Addo, Marylyn

AU - Eibach, Daniel

AU - Phillips, Richard O

AU - Owusu-Ofori, Alex

AU - Vinnemeier, Christof D

N1 - Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

PY - 2023/3

Y1 - 2023/3

N2 - OBJECTIVES: The global prevalence of intestinal extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) is approximately 17% in communities, with significant variations among regions. This longitudinal study aimed to assess the impact of antibiotic intake on the incidence of intestinal ESBL-PE in Ghanaian pharmacy customers outside of hospitals.METHODS: Screening for ESBL-PE was performed in four independent pharmacies in Kumasi, Ghana, using rectal swabs and an ESBL-PE-selective medium. Pharmacy customers purchasing antibiotics were recruited, and those buying non-antibiotic drugs served as controls. Participants who were negative for ESBL-PE provided follow-up swabs for up to 28 days.RESULTS: At baseline, 302 (75%) of 404 participants were colonized with ESBL-PE. Sixty-three participants who were negative for ESBL-PE at baseline received per-protocol follow-up, including 28 individuals who took antibiotics and 35 controls. The cumulative proportions of ESBL-PE in the antibiotics and control groups were 71% (20/28) and 54% (19/35) at the first follow-up (p 0.258), 86% (24/28) and 80% (28/35) at the second follow-up (p 0.741) and 86% (24/28) and 94% (33/35) at the third follow-up (p 0.393), respectively.DISCUSSION: The rate of intestinal ESBL-PE carriage among pharmacy customers outside of hospitals was higher than expected at baseline and further increased during the 28 days of follow-up, irrespective of antibiotic intake. This alarming finding needs to be considered in the antibiotic treatment of outpatients and emphasizes the urgent need for improved prevention strategies, development of new antibiotic drugs and potential future elimination strategies. Further longitudinal studies on ESBL-PE in African communities, also outside of pharmacy settings, are required.

AB - OBJECTIVES: The global prevalence of intestinal extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) is approximately 17% in communities, with significant variations among regions. This longitudinal study aimed to assess the impact of antibiotic intake on the incidence of intestinal ESBL-PE in Ghanaian pharmacy customers outside of hospitals.METHODS: Screening for ESBL-PE was performed in four independent pharmacies in Kumasi, Ghana, using rectal swabs and an ESBL-PE-selective medium. Pharmacy customers purchasing antibiotics were recruited, and those buying non-antibiotic drugs served as controls. Participants who were negative for ESBL-PE provided follow-up swabs for up to 28 days.RESULTS: At baseline, 302 (75%) of 404 participants were colonized with ESBL-PE. Sixty-three participants who were negative for ESBL-PE at baseline received per-protocol follow-up, including 28 individuals who took antibiotics and 35 controls. The cumulative proportions of ESBL-PE in the antibiotics and control groups were 71% (20/28) and 54% (19/35) at the first follow-up (p 0.258), 86% (24/28) and 80% (28/35) at the second follow-up (p 0.741) and 86% (24/28) and 94% (33/35) at the third follow-up (p 0.393), respectively.DISCUSSION: The rate of intestinal ESBL-PE carriage among pharmacy customers outside of hospitals was higher than expected at baseline and further increased during the 28 days of follow-up, irrespective of antibiotic intake. This alarming finding needs to be considered in the antibiotic treatment of outpatients and emphasizes the urgent need for improved prevention strategies, development of new antibiotic drugs and potential future elimination strategies. Further longitudinal studies on ESBL-PE in African communities, also outside of pharmacy settings, are required.

U2 - 10.1016/j.cmi.2022.09.008

DO - 10.1016/j.cmi.2022.09.008

M3 - SCORING: Journal article

C2 - 36150674

VL - 29

SP - 340

EP - 345

JO - CLIN MICROBIOL INFEC

JF - CLIN MICROBIOL INFEC

SN - 1198-743X

IS - 3

ER -